Update on the treatment of granulomatosis with polyangiitis (Wegener's)

被引：18

作者：

Langford C.A. ^{[1
]}

机构：

[1] Center for Vasculitis Care and Research, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, OH 44195, 9500 Euclid Avenue

来源：

Current Treatment Options in Cardiovascular Medicine | 2012年 / 14卷 / 2期

关键词：

ANCA; Treatment; Vasculitis; Wegener's;

D O I：

10.1007/s11936-012-0165-x

中图分类号：

学科分类号：

摘要：

Granulomatosis with polyangiitis (Wegener's) (GPA), formerly known as Wegener's granulomatosis, is a systemic vasculitis characterized by involvement of the upper airways, lungs, and kidneys. GPA shares many features with microscopic polyangiitis (MPA), so much so that recent trials have included both vasculitides. This article focuses on GPA only, as complete management includes modalities that are unique to this disease. The current treatment of GPA is stratified based on severity. For those patients who have active but non-severe GPA and do not have contraindications, methotrexate and glucocorticoids can induce and maintain remission. For patients with severe disease, options include glucocorticoids combined with either cyclophosphamide or rituximab. When cyclophosphamide is used, it is given for 3 to 6 months, after which time it is stopped and switched to methotrexate or azathioprine for remission maintenance. In randomized trials, rituximab was found to be as effective as cyclophosphamide to induce remission of severe active GPA. Given the recency of experience with rituximab, there remain a number of questions regarding relapse rate, use of repeat courses, long-term toxicity, and combination with maintenance agents. Until these questions are answered, the choice of whether to use cyclophosphamide or rituximab must be decided between the patient and physician. For patients with relapsing disease who have had prior cyclophosphamide exposure, rituximab is an excellent option. In newly diagnosed patients, the extensive experience with cyclophosphamide and its side effect profile must be weighed against these factors with rituximab. There has been limited experience with rituximab in patients with alveolar hemorrhage requiring mechanical ventilation or rapidly progressive glomerulonephritis requiring dialysis, as these patients were excluded from the largest randomized trial. Until such data become available, cyclophosphamide remains the agent with which there has been the greatest experience for efficacy in these settings. © Springer Science+Business Media, LLC 2012.

引用

页码：164 / 176

页数：12

共 48 条

[11]

Jones R.B., Tervaert J.W., Hauser T., Et al., Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis, N Engl J Med., 363, pp. 211-220, (2010)

[12]

Holle J.U., Gross W.L., Latza U., Et al., Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades, Arthritis Rheum., 63, pp. 257-266, (2011)

[13]

De Groot K., Harper L., Jayne D.R., Et al., Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial, Ann Intern Med., 150, pp. 670-680, (2009)

[14]

Talar-Williams C., Hijazi Y.M., Walther M.M., Linehan W.M., Hallahan C.W., Lubensky I., Kerr G.S., Hoffman G.S., Fauci A.S., Sneller M.C., Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis, Annals of Internal Medicine, 124, 5, pp. 477-484, (1996)

[15]

Le Guenno G., Mahr A., Pagnoux C., Et al., Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides, Arthritis Rheum., 63, pp. 1435-1445, (2011)

[16]

Monach P.A., Arnold L.M., Merkel P.A., Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A datadriven review, Arthritis Rheum., 62, pp. 9-21, (2010)

[17]

Hoffman G.S., Leavitt R.Y., Kerr G.S., Et al., The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate, Arthritis Rheum., 35, pp. 6112-6118, (1992)

[18]

Sneller M., Hoffman G., Talar-Williams C., Et al., Analysis of 42 Wegener's granulomatosis patients treated with methotrexate and prednisone, Arthritis Rheum., 38, pp. 608-613, (1995)

[19]

De Groot K., Reinhold-Keller E., Tatsis E., Et al., Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/ sulfamethoxazole, Arthritis Rheum., 39, pp. 2052-2061, (1996)

[20]

Langford C.A., Talar-Williams C., Sneller M.C., Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis, Arthritis Rheum., 43, pp. 1836-1840, (2000)

← 1 2 3 4 5 →